Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins

Antiviral Research

Volumn 72, Issue 1, 2006, Pages 49-59

  Baleja, James D ^a   Cherry, Jonathan J ^b   Liu, Zhiguo ^b   Gao, Hua ^b   Nicklaus, Marc C ^c   Voigt, Johannes H ^c   Chen, Jason J ^b   Androphy, Elliot J ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antiviral; E6; HPV 16; In silico screening; Papillomavirus; Protein protein interaction

Indexed keywords

ANTIVIRUS AGENT; HUMAN PAPILLOMA VIRUS 16 E6 PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DATA BASE; DRUG IDENTIFICATION; DRUG SCREENING; GEOMETRY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; THREE DIMENSIONAL IMAGING;

ANTIVIRAL AGENTS; BINDING SITES; DRUG DESIGN; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PROTEIN BINDING; REPRESSOR PROTEINS; ZINC FINGERS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 33747881135     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.03.014     Document Type: Article

References (56)

1. Alam S., Bromberg-White J., McLaughlin-Drubin M., Sen E., Bodily J.M., and Meyers C. Activity and therapeutic potential of ORI-1001 antisense oligonucleotide on human papillomavirus replication utilizing a model of dysplastic human epithelium. Anticancer Res. 25 (2005) 765-777
2. Alfandari J., Shnitman Magal S., Jackman A., Schlegel R., Gonen P., and Sherman L. HPV16 E6 oncoprotein inhibits apoptosis induced during serum-calcium differentiation of foreskin human keratinocytes. Virology 257 (1999) 383-396
3. Allen-Hoffmann B.L., Schlosser S.J., Ivarie C.A., Sattler C.A., Meisner L.F., and O'Connor S.L. Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. J. Invest. Dermatol. 114 (2000) 444-455
4. Arkin M.R., and Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3 (2004) 301-317
5. Be X., Hong Y., Wei J., Androphy E.J., Chen J.J., and Baleja J.D. Solution structure determination and mutational analysis of the papillomavirus E6 interacting peptide of E6AP. Biochemistry 40 (2001) 1293-1299
6. Beerheide W., Bernard H.U., Tan Y.J., Ganesan A., Rice W.G., and Ting A.E. Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein. J. Natl. Cancer Inst. 91 (1999) 1211-1220
7. Beerheide W., Sim M.M., Tan Y.J., Bernard H.U., and Ting A.E. Inactivation of the human papillomavirus-16 E6 oncoprotein by organic disulfides. Bioorg. Med. Chem. 8 (2000) 2549-2560
8. Beutner K.R., and Ferenczy A. Therapeutic approaches to genital warts. Am. J. Med. 102 (1997) 28-37
9. Bohl J., Das K., Dasgupta B., and Vande Pol S.B. Competitive binding to a charged leucine motif represses transformation by a papillomavirus E6 oncoprotein. Virology 271 (2000) 163-170
10. Butz K., Denk C., Ullmann A., Scheffner M., and Hoppe-Seyler F. Induction of apoptosis in human papillomavirus-positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 6693-6697
11. Chen J.J., Hong Y., Rustamzadeh E., Baleja J.D., and Androphy E.J. Identification of an alpha helical motif sufficient for association with papillomavirus E6. J. Biol. Chem. 273 (1998) 13537-13544
12. DiPaolo J.A., and Alvarez-Salas L.M. Advances in the development of therapeutic nucleic acids against cervical cancer. Exp. Opin. Biol. Ther. 4 (2004) 1251-1264
13. Elston R.C., Napthine S., and Doorbar J. The identification of a conserved binding motif within human papillomavirus type 16 E6 binding peptides, E6ap and E6bp. J. Gen. Virol. 79 (1998) 371-374
14. Fehrmann F., and Laimins L.A. Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 22 (2003) 5201-5207
15. Flores E.R., Allen-Hoffmann B.L., Lee D., Sattler C.A., and Lambert P.F. Establishment of the human papillomavirus type 16 (HPV-16) life cycle in an immortalized human foreskin keratinocyte cell line. Virology 262 (1999) 344-354
16. Galatin P.S., and Abraham D.J. A nonpeptidic sulfonamide inhibits the p53-MDM2 interaction and activates p53-dependent transcription in MDM2-overexpressing cells. J. Med. Chem. 47 (2004) 4163-4165
17. Gewin L., Myers H., Kiyono T., and Galloway D.A. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev. 18 (2004) 2269-2282
18. Huibregtse J.M., Scheffner M., and Howley P.M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 10 (1991) 4129-4135
19. Huibregtse J.M., Scheffner M., and Howley P.M. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol. Cell Biol. 13 (1993) 4918-4927
20. Kaufmann W.K., Schwartz J.L., Hurt J.C., Byrd L.L., Galloway D.A., Levedakou E., and Paules R.S. Inactivation of G2 checkpoint function and chromosomal destabilization are linked in human fibroblasts expressing human papillomavirus type 16 E6. Cell Growth Differ. 8 (1997) 1105-1114
21. Kelley M.L., Keiger K.E., Lee C.J., and Huibregtse J.M. The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. J. Virol. 79 (2005) 3737-3747
22. Klingelhutz A.J., Foster S.A., and McDougall J.K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380 (1996) 79-82
23. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., Chiacchierini L.M., and Jansen K.U. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347 (2002) 1645-1651
24. Lagrange M., Charbonnier S., Orfanoudakis G., Robinson P., Zanier K., Masson M., Lutz Y., Trave G., Weiss E., and Deryckere F. Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6. J. Gen. Virol. 86 (2005) 1001-1007
25. Lang P.T., Kuntz I.D., Maggiora G.M., and Bajorath J. Evaluating the high-throughput screening computations. J. Biomol. Screen. 10 (2005) 649-652
26. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001) 3-26
27. Liu X., Yuan H., Fu B., Disbrow G.L., Apolinario T., Tomaic V., Kelley M.L., Baker C.C., Huibregtse J., and Schlegel R. The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein. J. Biol. Chem. 280 (2005) 10807-10816
28. Liu Y., Chen J.J., Gao Q., Dalal S., Hong Y., Mansur C.P., Band V., and Androphy E.J. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J. Virol. 73 (1999) 7297-7307
29. Liu Y., Tergaonkar V., Krishna S., and Androphy E.J. Human papillomavirus type 16 E6-enhanced susceptibility of L929 cells to tumor necrosis factor alpha correlates with increased accumulation of reactive oxygen species. J. Biol. Chem. 274 (1999) 24819-24827
30. Liu Y., Liu Z., Androphy E., Chen J., and Baleja J.D. Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus. Biochemistry 43 (2004) 7421-7431
31. Malanchi I., Caldeira S., Krutzfeldt M., Giarre M., Alunni-Fabbroni M., and Tommasino M. Identification of a novel activity of human papillomavirus type 16 E6 protein in deregulating the G1/S transition. Oncogene 21 (2002) 5665-5672
32. McMurray H.R., Nguyen D., Westbrook T.F., and McAnce D.J. Biology of human papillomaviruses. Int. J. Exp. Pathol. 82 (2001) 15-33
33. Milne G.W., Nicklaus M.C., Driscoll J.S., Wang S., and Zaharevitz D. National cancer institute drug information system 3D database. J. Chem. Inf. Comput. Sci. 34 (1994) 1219-1224
34. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., Snijders P.J., and Meijer C.J. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348 (2003) 518-527
35. Nguyen M., Song S., Liem A., Androphy E., Liu Y., and Lambert P.F. A mutant of human papillomavirus type 16 E6 deficient in binding alpha-helix partners displays reduced oncogenic potential in vivo. J. Virol. 76 (2002) 13039-13048
36. Nomine Y., Charbonnier S., Ristriani T., Stier G., Masson M., Cavusoglu N., Van Dorsselaer A., Weiss E., Kieffer B., and Trave G. Domain substructure of HPV E6 oncoprotein: biophysical characterization of the E6 C-terminal DNA-binding domain. Biochemistry 42 (2003) 4909-4917
37. Nomine Y., Masson M., Charbonnier S., Zanier K., Ristriani T., Deryckere F., Sibler A.P., Desplancq D., Atkinson R.A., Weiss E., Orfanoudakis G., Kieffer B., and Trave G. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol. Cell 21 (2006) 665-678
38. Park R.B., and Androphy E.J. Genetic analysis of high-risk E6 in episomal maintenance of human papillomavirus genomes in primary human keratinocytes. J. Virol. 76 (2002) 11359-11364
39. Phelps W.C., Barnes J.A., and Lobe D.C. Molecular targets for human papillomaviruses: prospects for antiviral therapy. Antivir. Chem. Chemother. 9 (1998) 359-377
40. Scheffner M., Huibregtse J.M., and Howley P.M. Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 8797-8801
41. Scheffner M., Huibregtse J.M., Vierstra R.D., and Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75 (1993) 495-505
42. Scheffner M., and Whitaker N.J. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin. Cancer Biol. 13 (2003) 59-67
43. Schiller J.T., and Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat. Rev. Microbiol. 2 (2004) 343-347
44. Sherman L., Jackman A., Itzhaki H., Stöppler M.C., Koval D., and Schlegel R. Inhibition of serum- and calcium-induced differentiation of human keratinocytes by HPV16 E6 oncoprotein: role of p53 inactivation. Virology 237 (1997) 296-306
45. Sterlinko Grm H., and Banks L. Degradation of hDLg and MAGIs by human papillomavirus E6 is E6-AP-independent. J. Gen. Virol. 85 (2004) 2815-2819
46. Sterlinko Grm H., Weber M., Elston R., McIntosh P., Griffin H., Banks L., and Doorbar J. Inhibition of E6-induced degradation of its cellular substrates by novel blocking peptides. J. Mol. Biol. 335 (2004) 971-985
47. Stoppler H., Hartmann D.P., Sherman L., and Schlegel R. The human papillomavirus type 16 E6 and E7 oncoproteins dissociate cellular telomerase activity from the maintenance of telomere length. J. Biol. Chem. 272 (1997) 13332-13337
48. Storey A., Oates D., Banks L., Crawford L., and Crook T. Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. Nucleic Acids Res. 19 (1991) 4109-4114
49. Thomas J.T., Hubert W.G., Ruesch M.N., and Laimins L.A. Human papillomavirus type 31 oncoproteins E6 and E7 are required for maintenance of episomes during the viral life cycle in normal human keratinocytes. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 8449-8454
50. Thomas M.C., and Chiang C.M. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol. Cell 17 (2005) 251-264
51. Thompson D.A., Belinsky G., Chang T.H., Jones D.L., Schlegel R., and Munger K. The human papillomavirus-16 E6 oncoprotein decreases the vigilance of mitotic checkpoints. Oncogene 15 (1997) 3025-3035
52. Underwood M.R., Shewchuk L.M., Hassell A.M., and Phelps W.C. Searching for antiviral drugs for human papillomaviruses. Antivir. Ther. 5 (2000) 229-242
53. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., Wheeler C.M., Koutsky L.A., Malm C., Lehtinen M., Skjeldestad F.E., Olsson S.E., Steinwall M., Brown D.R., Kurman R.J., Ronnett B.M., Stoler M.H., Ferenczy A., Harper D.M., Tamms G.M., Yu J., Lupinacci L., Railkar R., Taddeo F.J., Jansen K.U., Esser M.T., Sings H.L., Saah A.J., and Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6 (2005) 271-278
54. Yamabhai M., and Kay B.K. Mapping protein-protein interactions with alkaline phosphatase fusion proteins. Methods Enzymol. 332 (2001) 88-102
55. Zanier K., Charbonnier S., Baltzinger M., Nomine Y., Altschuh D., and Trave G. Kinetic analysis of the interactions of human papillomavirus E6 oncoproteins with the ubiquitin ligase E6AP using surface plasmon resonance. J. Mol. Biol. 349 (2005) 401-412
56. Zimmermann H., Degenkolbe R., Bernard H.U., and O'Connor M.J. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J. Virol. 73 (1999) 6209-6219